Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company, has announced the grant of inducement equity awards to 9 newly hired non-executive employees. The awards include:
- Non-qualified stock options to purchase 8,870 shares of common stock
- Restricted stock units representing 17,745 shares of common stock
The stock options have an exercise price of $11.33 per share, equal to the closing price on October 7, 2024. They have a 10-year term and will vest over four years. The restricted stock units vest in approximately four equal annual installments beginning on November 15, 2025.
These inducement awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4) and will have terms consistent with the Company's 2018 Equity Incentive Plan.
Replimune Group, Inc. (NASDAQ: REPL), una azienda biotecnologica in fase clinica, ha annunciato l'assegnazione di premi azionari di indennizzo a 9 nuovi dipendenti non esecutivi. I premi includono:
- Opzioni su azioni non qualificate per l'acquisto di 8.870 azioni ordinarie
- Unità di azioni vincolate che rappresentano 17.745 azioni ordinarie
Le opzioni azionarie hanno un prezzo di esercizio di $11,33 per azione, pari al prezzo di chiusura del 7 ottobre 2024. Hanno una durata di 10 anni e matureranno nell'arco di quattro anni. Le unità di azioni vincolate maturano in circa quattro rate annuali uguali a partire dal 15 novembre 2025.
Questi premi di indennizzo sono stati approvati dal comitato compensi ai sensi della Regola di Quotazione 5635(c)(4) della Nasdaq e avranno termini coerenti con il Piano di Incentivazione Azionaria del 2018 della Società.
Replimune Group, Inc. (NASDAQ: REPL), una empresa biotecnológica en etapa clínica, ha anunciado la concesión de premios de acciones de inducción a 9 nuevos empleados no ejecutivos. Los premios incluyen:
- Opciones sobre acciones no calificadas para comprar 8,870 acciones ordinarias
- Unidades de acciones restringidas que representan 17,745 acciones ordinarias
Las opciones sobre acciones tienen un precio de ejercicio de $11.33 por acción, que es igual al precio de cierre del 7 de octubre de 2024. Tienen un plazo de 10 años y se adquirirán a lo largo de cuatro años. Las unidades de acciones restringidas se adquirirán en aproximadamente cuatro cuotas anuales iguales, comenzando el 15 de noviembre de 2025.
Estos premios de inducción fueron aprobados por el comité de compensación bajo la Regla de Cotización 5635(c)(4) de Nasdaq y tendrán términos consistentes con el Plan de Incentivos de Capital de 2018 de la Compañía.
Replimune Group, Inc. (NASDAQ: REPL), 임상 단계 생명공학 회사가 9명의 신규 비상임 직원에게 유도 주식 보상을 부여한다고 발표했습니다. 보상은 다음과 같습니다:
- 비자격 주식 옵션으로 8,870주 매입 가능
- 17,745주를 나타내는 제한된 주식 단위
주식 옵션의 행사가는 주당 $11.33로, 2024년 10월 7일의 종가와 동일합니다. 이 옵션은 10년의 만기를 가지며 4년에 걸쳐 분할됩니다. 제한된 주식 단위는 2025년 11월 15일부터 시작하여 대략 4회의 동등한 연간 할부로 분할됩니다.
이 유도 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회에서 승인되었으며, 회사의 2018 주식 인센티브 계획과 일치하는 조건을 가집니다.
Replimune Group, Inc. (NASDAQ: REPL), une société de biotechnologie en phase clinique, a annoncé l'octroi d'actions incitatives à 9 nouveaux employés non exécutifs. Les récompenses comprennent :
- Options d'achat d'actions non qualifiées pour 8 870 actions ordinaires
- Unités d'actions restreintes représentant 17 745 actions ordinaires
Les options d'achat d'actions ont un prix d'exercice de 11,33 $ par action, équivalent au prix de clôture du 7 octobre 2024. Elles ont une durée de 10 ans et seront acquises sur une période de quatre ans. Les unités d'actions restreintes seront acquises en environ quatre versements annuels égaux, à partir du 15 novembre 2025.
Ces récompenses incitatives ont été approuvées par le comité de rémunération conformément à la règle d'inscription 5635(c)(4) de Nasdaq et auront des conditions conformes au Plan d'Incentives en Actions de l'Entreprise de 2018.
Replimune Group, Inc. (NASDAQ: REPL), ein biotechnologisches Unternehmen in der klinischen Phase, hat die Vergabe von Anreizaktienoptionen an 9 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Optionen umfassen:
- Nicht qualifizierte Aktienoptionen zum Kauf von 8.870 Stammaktien
- Eingeschränkte Aktieneinheiten, die 17.745 Stammaktien repräsentieren
Die Aktienoptionen haben einen Ausübungspreis von 11,33 USD pro Aktie, was dem Schlusskurs vom 7. Oktober 2024 entspricht. Sie haben eine Laufzeit von 10 Jahren und werden über vier Jahre vesten. Die eingeschränkten Aktieneinheiten vesten in etwa vier gleichmäßigen jährlichen Raten, beginnend am 15. November 2025.
Diese Anreizvergaben wurden vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt und haben Bedingungen, die mit dem Eigenkapital-Vergütungsplan des Unternehmens von 2018 übereinstimmen.
- Attraction of new talent with equity incentives
- Alignment of employee interests with company performance through stock options and RSUs
- Potential dilution of existing shareholders' equity
WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 9 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 8,870 shares of the Company's common stock and restricted stock units representing an aggregate of 17,745 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
What types of inducement equity awards did Replimune (REPL) grant to new employees?
What is the exercise price of the stock options granted by Replimune (REPL)?
How do the vesting schedules work for Replimune's (REPL) inducement equity awards?
Under which Nasdaq rule were Replimune's (REPL) inducement awards approved?
